Relation of Timing of Percutaneous Coronary Intervention on Outcomes in Patients With Non-ST Segment Elevation Myocardial Infarction.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 10 07 2020
revised: 01 09 2020
accepted: 04 09 2020
pubmed: 19 9 2020
medline: 1 1 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

International guidelines suggest revascularization within 24 hours in non-ST segment elevation myocardial infarction (NSTEMI). Within a large population cohort study, we aimed to explore clinical practice regarding timing targets for percutaneous coronary intervention (PCI) in NSTEMI. The Victorian Cardiac Outcomes Registry was established in 2013 as a state-wide clinical quality registry, pooling data from public and private PCI capable centers. Data were collected on 11,852 PCIs performed for NSTEMI from 2014 to 2018. Patients were divided into 3 groups by time of symptom onset to PCI (<24 hours; 24 to 72 hours; >72 hours). We performed multivariable logistic regression analysis conditional on several baseline covariates in investigating the impact of timing of PCI in NSTEMI on clinical outcomes. Patients who underwent PCI within 24 hours represented 18.4% (n = 2,178); 24 to 72 hours 45.8% (n = 5,434); >72 hours 35.8% (n = 4,240). Patients waiting longer for PCI were older (62.6 ± 12.2 vs 64.8 ± 12.6 vs 67.0 ± 12.7, p <0.001), more likely to be female (23.1% vs 24.2% vs 26.4%, p = 0.007), and have diabetes (18.6% vs 21.1% vs 27.1%, p <0.001). Multivariate logistic regression found that as compared with PCI <24 hours, PCI 24 to 72 hours and PCI >72 hours of symptom onset were associated with a decreased risk of 30-day mortality (odds ratio 0.55; 95% confidence interval 0.35 to 0.86, p = 0.008 and odds ratio 0.64; 95% confidence interval 0.35 to 1.01, p = 0.053, respectively). There was no significant difference in 30-day mortality between groups following exclusion of patients presenting with cardiogenic shock or out of hospital cardiac arrest requiring intubation. In conclusion, many registry patients undergo PCI outside the 24-hour window following NSTEMI. This delay is at odds with current guideline recommendations but does not appear to be associated with an increased mortality risk.

Identifiants

pubmed: 32946855
pii: S0002-9149(20)30946-2
doi: 10.1016/j.amjcard.2020.09.011
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-23

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Auteurs

Riley J Batchelor (RJ)

Department of Cardiology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia.

Diem Dinh (D)

Monash University, Melbourne, Australia.

Angela Brennan (A)

Monash University, Melbourne, Australia.

Nathan Wong (N)

Department of Cardiology, Alfred Health, Melbourne, Australia.

Jeffrey Lefkovits (J)

Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia.

Christopher Reid (C)

Monash University, Melbourne, Australia; Curtin University, Perth, Australia.

Stephen J Duffy (SJ)

Department of Cardiology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia.

William Chan (W)

Department of Cardiology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia; Department of Cardiology, Western Health, Melbourne, Australia.

Nicholas Cox (N)

Monash University, Melbourne, Australia; Department of Cardiology, Western Health, Melbourne, Australia.

Danny Liew (D)

Monash University, Melbourne, Australia.

Dion Stub (D)

Department of Cardiology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia; Department of Cardiology, Western Health, Melbourne, Australia. Electronic address: d.stub@alfred.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH